Joydeep Goswami


President, Clinical Next Gen Sequencing and Oncology Division (CSD) Life Sciences Solutions, Thermo Fisher Scientific Joydeep Goswami has been President, Clinical Next Generation Sequencing and Oncology Division (CSD) since July 2016. CSD is focused on serving the targeted sequencing needs of customers in research and clinical applications, with an emphasis on oncology.

Prior to his current role, Joydeep was the VP/ GM of the Protein and Cell Analysis (PCA) business at Thermo Fisher, between April 2015 and July 2016. The PCA business includes the imaging and dyes, flow cytometry, protein prep and assays, protein electrophoresis, immunoassays and mass spec reagent portfolios. He joined Thermo Fisher as President of Asia Pacific and Japan, Life Sciences Solutions in 2014 through the acquisition of Life Technologies. He had been responsible for the Life Technologies APJ Region since September 2013, which covers over 40 countries excluding Greater China. Joydeep has held various executive positions at Life Technologies. As the President of Life Technologies Japan, he led the largest business country next to the United States between April 2011 and August 2013. Prior to this role he served as Vice President and General Manager of Primary and Stem Cell Systems and Vice President of Stem Cells and Regenerative Medicine. Joydeep joined Life Technologies (then Invitrogen) in 2003 as Director, Corporate Development, Global Head of Licensing. Before joining Life Technologies, Joydeep worked at McKinsey & Company, serving clients primarily in the pharmaceutical industry but also in the medical products, chemical, and technology industries in the U.S., Europe, Asia and Latin America. Joydeep has a Ph.D. and M.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.B.A. from MIT Sloan School of Management. He holds a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology.

Listen to the interview with Joydeep (published August 2017) https://mendelspod.com/podcasts/thermo-pfizer-and-novartis-pull-first-ng...



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup